Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study

Autor: Siyue Jia, Zundong Yin, Hongxing Pan, Fuzhen Wang, Xiaoqiang Liu, Qing Wang, Li Zhang, Jihai Tang, Hao Yang, Jiangbo Du, Zhiguo Wang, Pengfei Jin, Zhihang Peng, Rong Tang, Guodong Kang, Xuewen Wang, Simin Li, Weixiao Wang, Jingxin Li, Hongbing Shen, Fengcai Zhu
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Emerging Microbes and Infections, Vol 13, Iss 1 (2024)
Druh dokumentu: article
ISSN: 22221751
2222-1751
DOI: 10.1080/22221751.2024.2332660
Popis: ABSTRACTEffectiveness of heterologous booster regimes with ad5 vectored COVID-19 vaccine in a large, diverse population during the national-scale outbreak of SARS-CoV-2 omicron predominance in China has not been reported, yet. We conducted a large-scale cohort-control study in six provinces in China, and did a retrospective survey on the COVID-19 attack risk during this outbreak. Participant aged ≥18 years in five previous trials who were primed with 1 to 3 doses of ICV received heterologous booster with either intramuscular or orally inhaled ad5 vectored COVID-19 vaccine were included in the heterologous-trial cohort. We performed propensity score-matching at a ratio of 1:4 to match participants in the heterologous-trial cohort individually with the community individuals who received three-dose of ICV as a control (ICV-community cohort). From February 4 to April 10, 2023, 41504 (74.5%) of 55710 individuals completed the survey. The median time since the most recent vaccination to the onset of the symptoms of COVID-19 was 303.0 days (IQR 293.0-322.0). The attack rate of COVID-19 in the heterologous-trial cohort was 55.8%, while that in the ICV-community cohort was 64.6%, resulting in a relative effectiveness of 13.7% (95% CI 11.9 to 15.3). In addition, a higher relative effectiveness against COVID-19 associated outpatient visits, and admission to hospital was demonstrated, which was 25.1% (95% CI 18.9 to 30.9), and 48.9% (95% CI 27.0 to 64.2), respectively. The heterologous booster with ad5 vectored COVID-19 vaccine still offered some additional protection in preventing COVID-19 breakthrough infection versus homologous three-dose regimen with ICV, 10 months after vaccination.
Databáze: Directory of Open Access Journals
Externí odkaz: